1.         Greider, C. W. & Blackburn, E. H. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 337, 331–337 (1989).

2.         Kim, N. W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 266, 2011–2015 (1994).

3.         Shay, J. W. & Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer Part A 33, 787–791 (1997).

4.         Wright, W. E., Piatyszek, M. A., Rainey, W. E., Byrd, W. & Shay, J. W. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 18, 173–179 (1996).

5.         Bertuch, A. A. The molecular genetics of the telomere biology disorders. RNA Biology 13, 696–706 (2016).

6.         Armanios, M. & Blackburn, E. H. The telomere syndromes. Nature reviews. Genetics 13, 693–704 (2012).

7.         Batista, L. F. Z. et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 474, 399–404 (2011).

8.         Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science. 339, 957–959 (2013).

9.         Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science. 339, 959–961 (2013).

10.       Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. U. S. A. 110, 6021–6026 (2013).

11.       Huang, F. W. et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis 4, e176 (2015).

12.       Stern, J. L., Theodorescu, D., Vogelstein, B., Papadopoulos, N. & Cech, T. R. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev. 29, 2219–2224 (2015).

13.       Vinagre, J. et al. Telomerase promoter mutations in cancer: An emerging molecular biomarker? Virchows Archiv 465, 119–133 (2014).

14.       Ramlee, M. K., Wang, J., Toh, W. X. & Li, S. Transcription regulation of the human telomerase reverse transcriptase (hTERT) gene. Genes 7, (2016).

15.       Campos, M. A. et al. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol. 80, 660-669.e6 (2019).

16.       Chan, A. K. Y. et al. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod. Pathol. 28, 177–186 (2015).

17.       George, J. R. et al. Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC. J. Clin. Endocrinol. Metab. 100, E1550–E1559 (2015).

18.       Simon, M. et al. TERT promoter mutations: A novel independent prognostic factor in primary glioblastomas. Neuro. Oncol. 17, 45–52 (2015).

19.       Lee, S. et al. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci. Rep. 5, 11200 (2015).

20.       Bahrami, A. et al. TERT promoter mutations and prognosis in solitary fibrous tumor. Mod. Pathol. 29, 1511–1522 (2016).

21.       Nagore, E., Rachakonda, S. & Kumar, R. TERT promoter mutations in melanoma survival. Oncotarget 10, 1546–1548 (2019).

22.       Vuong, H. G. et al. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data. Critical Reviews in Oncology/Hematology 120, 1–9 (2017).

23.       Rachakonda, P. S. et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc. Natl. Acad. Sci. U. S. A. 110, 17426–17431 (2013).

24.       Borah, S. et al. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science. 347, 1006–1010 (2015).

25.       Mancini, A. et al. Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. Cancer Cell 34, 513–528 (2018).

26.       Stern, J. L. et al. Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers. Mol. Cancer Res. Accepted, (2020).

27.       Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C. & Kuperwasser, C. Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. Cell Stem Cell 24, 65–78 (2019).

28.       Williams, E. D., Gao, D., Redfern, A. & Thompson, E. W. Controversies around epithelial–mesenchymal plasticity in cancer metastasis. Nat. Rev. Cancer 19, 716–732 (2019).

29.       Keyes, B. E. & Fuchs, E. Stem cells: Aging and transcriptional fingerprints. Journal of Cell Biology 217, 79–92 (2018).

30.       Ermolaeva, M., Neri, F., Ori, A. & Rudolph, K. L. Cellular and epigenetic drivers of stem cell ageing. Nature Reviews Molecular Cell Biology 19, 594–610 (2018).

31.       Jaskelioff, M. et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 469, 102–107 (2011).

32.       Sahin, E. & DePinho, R. A. Axis of ageing: Telomeres, p53 and mitochondria. Nature Reviews Molecular Cell Biology 13, 397–404 (2012).

33.       Bernardes de Jesus, B. et al. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol. Med. 4, 691–704 (2012).